reviewed april 2026|next review october 2026|88 physicians psi has verified|5579 published studies
Liraglutide
Liraglutide is a GLP-1 receptor agonist approved by the FDA as Victoza for type 2 diabetes, Saxenda for chronic weight management in adults and adolescents, and with a cardiovascular risk reduction indication. It was the first GLP-1 medication approved for obesity.
Evidence landscape: 5579 published studies
5,579 published items: 36 human studies and 107 animal studies. One of the deepest clinical evidence bases in the GLP-1 class, supporting four FDA-approved indications.
- 36 Human
- 107 Animal
- 57 Reviews
- 5379 Other research
FDA-approved prescription medicine in the United States under Victoza (type 2 diabetes) and Saxenda (chronic weight management in adults and adolescents aged 12 and older). Also carries a cardiovascular risk reduction indication.
One of the deepest evidence bases in metabolic medicine, spanning the LEAD program (diabetes), SCALE program (weight), LEADER (cardiovascular outcomes), and SCALE Teens (pediatric obesity). Over a decade of clinical use.
The LEADER trial demonstrated a 13% reduction in major adverse cardiovascular events in 9,340 adults with type 2 diabetes at high cardiovascular risk over a median 3.8 years. The first cardiovascular outcomes benefit shown for a GLP-1 agonist.
PSI Assessment
The modern era of GLP-1 weight loss medications began with liraglutide. Approved as Saxenda for weight management in 2014, it was the first GLP-1 agonist to receive an obesity indication and the medication that proved the class could treat more than diabetes. The LEADER cardiovascular outcomes trial added a 13% reduction in major cardiovascular events. The evidence base spans over a decade of clinical use. The open question today is not whether liraglutide works, but how it positions against newer weekly agents that produce roughly twice the weight loss.
The first GLP-1 agonist approved for obesity. The first with a cardiovascular outcomes benefit. The longest real-world safety track record in the class.
The mechanism is GLP-1 receptor agonism: liraglutide mimics a gut hormone that suppresses appetite, slows gastric emptying, and enhances insulin secretion. A fatty acid side chain extends the half-life to approximately 13 hours, enabling once-daily dosing. The 97% amino acid homology to native GLP-1 is the highest of any approved GLP-1 medication. What distinguishes liraglutide from semaglutide and tirzepatide is the longest real-world safety track record in the class and an FDA-approved pediatric obesity indication.
What the evidence supports
FDA-approved for type 2 diabetes, weight management in adults and adolescents, and cardiovascular risk reduction. The LEADER trial demonstrated 13% MACE reduction. Over a decade of clinical use with millions of patient-years of safety data.
What is not yet established
Whether liraglutide retains a meaningful clinical niche as semaglutide and tirzepatide become standard of care. Head-to-head outcomes comparison against newer weekly agents. Long-term weight maintenance beyond trial durations.
Research Evidence
The findings below cover what a decade of clinical use has established and how liraglutide positions in the current landscape.
Evidence by condition
Evidence dimensions across liraglutide's approved and investigated indications. Weight management, diabetes, and cardiovascular risk reduction have the deepest evidence with replication across multiple Phase III programs.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Weight Management | ||||
| Type 2 Diabetes | ||||
| Cardiovascular Risk Reduction | ||||
| Pediatric Obesity | ||||
| Non-alcoholic Steatohepatitis (MASH) |
The SCALE Obesity and Prediabetes trial reported mean weight loss of 8.0% at the 3.0 mg dose over 56 weeks versus 2.6% on placebo. 63% of participants achieved at least 5% weight loss. That result drove the 2014 Saxenda approval, the first obesity indication for a GLP-1 medication.
The 8% magnitude is meaningful relative to most pharmacologic approaches to weight, though it sits below the 15% achieved by semaglutide and the 22% by tirzepatide in their own Phase III programs.
The LEADER cardiovascular outcomes trial enrolled 9,340 adults with type 2 diabetes and high cardiovascular risk, followed for a median 3.8 years. A 13% relative risk reduction in the primary composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The first cardiovascular benefit demonstrated for a GLP-1 agonist.
The SELECT trial later extended cardiovascular benefit to semaglutide in a broader obesity-without-diabetes population. LEADER remains the foundational cardiovascular evidence for the class in secondary prevention.
Three features distinguish liraglutide from newer agents. Daily subcutaneous dosing allows for finer titration than weekly alternatives. The FDA adolescent obesity indication (SCALE Teens, Kelly 2020) is unique in the class. The post-marketing safety database is the largest in the GLP-1 class.
Newer weekly agents produce greater weight loss, but liraglutide retains distinct clinical niches: pediatric obesity, patients who need daily-dose titration for tolerability, and the maturity advantage of over a decade of clinical use.
36 Human|107 Animal|57 Reviews
View all 5579 indexed studiesHow Liraglutide Works
Liraglutide is a synthetic analog of human GLP-1, engineered for a 13-hour half-life that allows once-daily dosing. It retains 97% amino acid homology with the natural hormone, the highest of any approved GLP-1 medication.
Liraglutide mimics a hormone your gut releases after eating that tells your brain you are full and tells your pancreas to release insulin. By extending how long that signal lasts, it reduces appetite and improves blood sugar control. It works with your body's natural system rather than bypassing it.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Liraglutide is a 97% amino acid homolog of human GLP-1(7-37) with a single substitution (Arg34Lys) and a C16 palmitoyl fatty acid attached via a glutamic acid spacer at Lys26. The fatty acid tail promotes reversible binding to serum albumin, extending the half-life to approximately 13 hours and enabling once-daily subcutaneous dosing. It activates the GLP-1 receptor on pancreatic beta cells (enhancing glucose-dependent insulin secretion), alpha cells (suppressing glucagon), hypothalamic neurons (reducing appetite and promoting satiety), and gastric smooth muscle (slowing gastric emptying). Central nervous system effects on reward pathways contribute to reduced food-seeking behavior.
What is Liraglutide being studied for?
Researchers are studying Liraglutide across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Liraglutide overall. This means a compound can have human studies for one condition but only animal data for another.
Weight Management
·FDA ApprovedThe SCALE program demonstrated mean weight loss of 8.0% at the 3.0 mg dose over 56 weeks. FDA-approved as Saxenda for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Limitations: Weight loss magnitude is lower than semaglutide (~15%) and tirzepatide (~22%). Daily injection requirement is a practical consideration versus weekly alternatives. Weight regain after discontinuation is typical.
Type 2 Diabetes
·FDA ApprovedThe LEAD program demonstrated HbA1c reductions of 1.0 to 1.5 percentage points across six Phase III trials. FDA-approved as Victoza for type 2 diabetes.
Limitations: Newer GLP-1 agonists and the dual agonist tirzepatide have demonstrated greater glycemic efficacy. Daily dosing is a practical disadvantage relative to weekly alternatives.
Cardiovascular Risk Reduction
·FDA ApprovedThe LEADER trial demonstrated a 13% reduction in major adverse cardiovascular events in 9,340 adults with type 2 diabetes at high cardiovascular risk. Cardiovascular risk reduction is on the Victoza label.
Limitations: Benefit established in type 2 diabetes with high cardiovascular risk. Generalization to primary prevention populations is not established.
Pediatric Obesity
·FDA ApprovedThe SCALE Teens trial demonstrated BMI reduction versus placebo in adolescents aged 12 to under 18 with obesity. FDA-approved as Saxenda for this population, the first GLP-1 approved for adolescent obesity.
Limitations: Long-term data on growth, puberty, and metabolic trajectory during development remains under active post-marketing surveillance.
Non-alcoholic Steatohepatitis (MASH)
·Human TrialsThe LEAN Phase II trial demonstrated histological resolution of NASH in 39% of liraglutide-treated patients versus 9% on placebo over 48 weeks. Not FDA-approved for this indication.
Limitations: Phase II sample size. Phase III confirmation for MASH has not been conducted with liraglutide. Semaglutide is the GLP-1 that advanced to Phase III for MASH.
Safety and Regulatory Status
FDA Status: FDA-approved in the United States as Victoza (type 2 diabetes, 2010) and Saxenda (weight management, 2014). Cardiovascular risk reduction indication on the Victoza label. Adolescent obesity indication (ages 12 and older) on Saxenda.
Prescription status: Prescription-only. A doctor can write a prescription for it through standard pharmacies. Biosimilar competition is emerging as patent protections expire.
International status: Approved in major international jurisdictions including the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency, and Health Canada under the same brand names.
Common side effects are gastrointestinal: nausea, diarrhea, constipation, and vomiting. These are dose-dependent and typically diminish with continued treatment. The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent studies that has not been confirmed in humans. Pancreatitis and gallbladder disease are rare but documented class effects.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Liraglutide discussion.
Comparison and Related Research
Liraglutide is most often compared with other GLP-1 and multi-receptor agonists in the metabolic class. The comparisons below outline how each differs in mechanism, evidence base, and dosing.
Head-to-head comparisons
Full research comparisons covering Liraglutide and another peptide side by side.
Liraglutide vs Semaglutide
Research comparison of semaglutide and liraglutide, two GLP-1 receptor agonists with different pharmacokinetics and clinical outcomes. Evidence levels, dosing, efficacy, and safety analyzed.
View full comparisonLiraglutide vs Ozempic (semaglutide)
Neutral, factual comparison of semaglutide and liraglutide as GLP-1 receptor agonists in the context of type 2 diabetes, dosing, weight effects, and cardiovascular outcomes.
View full comparisonLiraglutide vs Wegovy (semaglutide)
Neutral, factual comparison of liraglutide (Saxenda) and semaglutide (Wegovy) as FDA-approved GLP-1 medications for chronic weight management, including dosing, outcomes, and tolerability context.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The SCALE Obesity and Prediabetes trial. 3,731 adults with overweight or obesity over 56 weeks. Mean weight loss of 8.0% at the 3.0 mg dose versus 2.6% on placebo. Established the weight-management indication that led to Saxenda approval.Pi-Sunyer X et al., 2015 in N Engl J Med. View on PubMed
- 2.The LEADER cardiovascular outcomes trial. 9,340 adults with type 2 diabetes and high cardiovascular risk over a median 3.8 years. 13% relative risk reduction in major adverse cardiovascular events. First cardiovascular outcomes benefit demonstrated for a GLP-1 agonist.Marso SP et al., 2016 in N Engl J Med. View on PubMed
- 3.Head-to-head trial of liraglutide against exenatide twice-daily in type 2 diabetes. Liraglutide produced greater HbA1c reduction and comparable weight loss with a simpler dosing schedule.Buse JB et al., 2009 in Lancet. View on PubMed
- 4.Phase III trial in adolescents aged 12 to under 18 with obesity. Mean BMI reduction favored liraglutide over placebo. Basis for the first pediatric obesity indication for a GLP-1 medication.Kelly AS et al., 2020 in N Engl J Med. View on PubMed
- 5.Phase II trial in adults with biopsy-proven NASH. 39% of liraglutide-treated patients achieved histological resolution of steatohepatitis versus 9% on placebo. Early signal for hepatic outcomes in the class.Armstrong MJ et al., 2016 in Lancet. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.